Nanobiotix Stock
Price
Target price
€5.20
€5.20
-1.790%
-0.095
-1.790%
-
15.04.24 / Stuttgart Stock Exchange
WKN: A1J7EB / Name: Nanobiotix / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Nanobiotix Stock
A loss of -1.790% shows a downward development for Nanobiotix.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Nanobiotix stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Nanobiotix in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Nanobiotix vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Nanobiotix | -1.790% | -5.192% | -3.022% | 53.924% | -17.523% | -61.630% | -55.764% |
| Valneva SE | -4.230% | 4.526% | 12.171% | -24.355% | -17.677% | -67.899% | 13.797% |
| Transgene S.A. | 1.310% | 20.175% | 22.103% | -27.282% | 2.239% | -49.353% | -53.638% |
| Avadel Pharmaceuticals plc ADR | 0.670% | 0.000% | 2.721% | 63.243% | 14.394% | - | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-05-11
Upon first glance, the financials of Nanobiotix, a company from the Biotechnology & Medical Research industry, seem to be facing a challenging financial situation. The company has continuously reported net losses and has a negative stockholder's equity as of the end of 2022. However, it is essential to dive deeper into the company's financial statements to better understand the underlying factors contributing to its current position.
Pros
Strong liquidity position: Nanobiotix's cash and short-term investments stood at €41,388,000 at the end of 2022, indicating a solid liquidity position to continue funding its research and development activities.